Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III crossover trial of N-acetyl-L-leucine in Niemann-Pick disease type C
NL-OMON53762Phase 3Active, not recruiting
- Sponsor
- IntraBio
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of levacetylleucine in Niemann-Pick disease type C (NPC) (2 arms), sponsored by IntraBio. Primary endpoints: Primary endpoint (Europe and Australia) and Primary endpoint (United States). Started Jul 2022; status: active, not recruiting.
02
Drugs
levacetylleucine
03
Conditions
Niemann-Pick disease type C (NPC)
Beyond the preview
Go deeper on NL-OMON53762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53762.